The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from two new analyses of STELARA? (ustekinumab) for the treatment of adults with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). In a modelled analysis focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was when STELARA was used as a first-line advanced therapy for bio-na?ve patients with moderately to severely active UC relative to outcomes associated with second- or third-line use (P0540). Additionally, in a separate real-world claims analysis, a greater proportion of bio-na?ve patients who started biologic therapy with STELARA (n=948) for moderately to severely active CD showed persistence at 12 months versus adalimumab (n=4,143) (P0525). These data are among 16 abstracts, including one oral presentation, presented at the 2021 American College of Gastroenterology Annual Scientific Meeting, which is taking place October 22-27 in Las Vegas, Nevada. Initiating STELARA as a first-line advanced therapy for UC in a hybrid decision tree model resulted in more favorable patient outcomes in terms of increased amount of time spent in remission or response and the postponing of surgery compared with second-line and third-line use. When used first-line, STELARA-treated patients in the cohort model spent on average: 8.5 months (71% of the time) in remission or response over one year. 23.1 months (64% of the time) in remission or response over three years. 32.2 months (54% of the time) in remission or response over five years. When STELARA was used in the second-line setting, patients spent on average: 7.9 months (66% of the time) in remission or response over one year.14.5 months (40% of the time) in remission or response over three years.17.5 months (29% of the time) in remission or response over five years. Modelled use of STELARA in the first- versus second-line reduced time affected by active UC by 0.6, 8.3, and 13.8 months over one, three, and five years, respectively. When compared to third-line, first-line use of STELARA suggested even greater reductions at the one-year (0.9 months), three-year (9 months), and five-year (14.5 months) timepoints. Future research is required to generate long-term clinical data to confirm these results.